7-aminocephalosporanic acid is abbreviated as 7-ACA, white or almost white crystalline powder, 7-ACA is an important nucleus in synthesis of cephalosporin antibiotics, in the nucleus 7 and 3 chemical transformation can be used to prepare many cephalosporins: cefazolin sodium, cefotaxime sodium, ceftriaxone sodium, cefoperazone sodium, sodium ceftazidime, cefuroxime sodium.
7-ACA represents the key intermediate for the synthesis of the API which is obtained after (bio-) chemical derivatization at position 3′ and 7′. Cephalosporin C can be converted to 7-ACA by either a chemical or an enzymatic removal of the 7-amino adipoyl side chain. 7-Aminocephalosporanic Acid [chemically, 3-(Acetyloxy-methyl)-7-amino- 8-oxo-5-thia-1- azabicyclo (4.2.0) oct-2-ene-2-carboxylic acid] is the active nucleus for the synthesis of cephalosporins and intermediates.
- Potent inhibitor of bacterial (S. aureus) β-lactamase.
- Antibacterial; Bacterial transpeptidase inhibitor
- Antibiotics use for the treatment of a bacterial infection.
- Used in infections of the respiratory and urinary tracts, skin, and bones.
Indian pharmaceutical companies now supply nearly all the country's demand for formulations and nearly 70% of its demand for bulk drugs. The Indian firms produce nearly 60,000 generic brands in 60 therapeutic categories and between 350 and 400 bulk drugs. India's drug market consists mainly of second and third generation drugs no longer subject to patent protection in the developed world.
India has the world's third largest active pharmaceutical ingredients (API) for the industry valued at a little less than USD 2 bn. Top 5 API producers account for approximately 6.5 %. The leading APIs are anti-infectives, gastrointestinal, cardiovascular and respiratory drugs. The Chemical Pharmaceutical Generic Association (CPA) projects that India's share of the world API market will grow by 10.5% by 2010 as patented blockbuster drugs lose their patent protection. The CPA also expects that the domestic Indian market for APIs, both generic and branded, will rise from USD 755 mn in 2005 to USD 1.9 bn in 2010. The API market in India to grow at a CAGR of 10.76 percent. As a whole there is a good scope for new entrepreneur to invest in this business.
